
    
      The study is a single arm, open label, phase II, international, multi-centre study. Sample
      size will be 25 evaluable patients with a recruitment period of 2 years. Patients will be
      administered 200mg pembrolizumab IV every 3 weeks up to 35 cycles or 2 years. Patients will
      be followed-up for 1 year.
    
  